Abstract: This invention is in the field of glucose isomerization enzymes. More specifically, the invention is directed to a novel xylose isomerase, a process for the preparation of this enzyme, the use of this enzyme in glucose isomerization processes, and glucose isomerization processes.The enzyme is preferrably derived from Thermotoga maritima or Thermotoga neapolitana. The enzyme has a temperature optimum above 90.degree. C., pH optimum in the range of from 6 to 7 and a residual activity at 90.degree. C. of more than 40% after 30 minutes and/or residual activity at 98.degree. C. of more than 20% after 30 minutes. The enzyme can also be in immobilized form.
Type:
Grant
Filed:
April 13, 1993
Date of Patent:
December 7, 1993
Assignees:
Novo Nordisk A/S, The Johns Hopkins University
Inventors:
Robert L. Starnes, Robert M. Kelly, Stephen H. Brown
Abstract: The present invention relates to therapeutically active piperidine compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
Abstract: The invention relates to novel substituted 2-imidazolines (I) having a lowering effect on blood glucose in mammals, to their preparation, to pharmaceutical compostions containing them and to their use.
Abstract: Azacyclic compounds selected from the group consisting of ##STR1## wherein R.sup.1 is H or C.sub.1-6 -alkylR.sup.3 is ##STR2## wherein R' is C.sub.3-8 -alkyl, cyclopropyl, C.sub.4-8 -cycloalkyl, benzyl which may be substituted, or C.sub.1-4 -alkoxy-C.sub.1-4 -alkyl, andR" is H or C.sub.1-8 -alkyl or C.sub.1-6 -alkoxy or C.sub.1-4 -alkoxy-C.sub.1-4 -alkyl or aryl, andR'" is H or C.sub.1-6 -alkyl or C.sub.4-8 -cycloalkyl; andR.sup.4 is H, C.sub.1-8 -alkyl or Cl; and ##STR3## provided that R.sup.3 is not ##STR4## wherein R' is C.sub.3-8 -alkyl, cyclopropyl or C.sub.1-3 -alkoxymethyl, and provided that R.sup.3 is not --CH.dbd.N--OR'", wherein R'" is H or C.sub.1-6 -alkyl, when the compounds of formula I is ##STR5## and a salt thereof with a pharmaceutically-acceptable acid. The new compounds are useful in improving the cognitive functions of the forebrain and hippocampus of mammals, and are useful in the treatment of Alzheimer's disease.
Type:
Grant
Filed:
November 8, 1988
Date of Patent:
November 16, 1993
Assignee:
Novo Nordisk A/S
Inventors:
Lone Nielson, Frank Watjen, Jens W. Kindtler, Preben H. Olesen, Per Sauerberg
Abstract: The present invention relates to therapeutically active piperidine compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
Abstract: Imidazotriazoloquinazoline compounds having the general formula ##STR1## wherein A together with the .alpha.-marked carbon atom and the .beta.-marked nitrogen atom is one of the groups ##STR2## cyano or CO.sub.2 R.sup.5, wherein R.sup.5 is H, alkyl, cycloalkyl, trifluoromethyl or alkoxymethyl; and R.sup.2, R.sup.3 and R.sup.4 independently are H, hydroxy, halogen, CN, alkyl, alkenyl, alkynyl, trifluoromethyl, alkoxy, dialkylaminoalkoxy, aralkoxy, aryloxy which may be substituted, acyclic amino group, or NR.sup.6 R.sup.7, wherein R.sup.6 and R.sup.7 independently are H or alkyl.The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, antipsychotics, antiemetics, or in improving the cognitive function of the brain of mammals, or as benzodiazepine antagonsists.
Abstract: The present invention relates to therapeutically active piperidine compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
Abstract: A process for expression of a protein product in Aspergillus is disclosed. The process comprises transforming an Aspergillus strain with a vector system comprising DNA-sequences encoding a promoter including upstream activating sequences derived from an A. niger amylase, a suitable marker for selection of transformants, and a DNA-sequence encoding the desired protein product. The process enables industrial production of many different polypeptides and proteins in Aspergillus, preferably A. niger. Examples of such products are chymosin or prochymosin and other rennets, proteases, lipases and amylases. Also disclosed is an effective promoter for expression of a protein in Aspergillus, preferably Aspergillus niger being derived from a gene encoding an A. niger amylase. The A. niger amylases are the neutral and acid stable .alpha.-amylases and a new amylase not so far described and designated XA amylase. Also disclosed is the novel amylase from A. niger XA amylase.
Abstract: Indole derivatives of formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 may be hydrogen or lower alkyl optionally substituted by halogen; A.sup.1 represents a straight or branched alkylene chain containing from 2 to 4 carbon atoms; R.sup.5 is hydrogen or a straight or branched alkyl group; A.sup.2 is a straight or branched, saturated or unsaturated hydrocarbon chain containing from 2 to 6 carbon atoms; and R.sup.6 is selected from a group consisting of various structures, have been found to exhibit central nervous system activities.
Type:
Grant
Filed:
April 7, 1992
Date of Patent:
October 5, 1993
Assignee:
Novo Nordisk A/S
Inventors:
Lone Jeppesen, Peter H. Andersen, Louis B. Hansen, Peter Farrup, John B. Hansen
Abstract: Non-surgically correctable infertility or sub-fertility in adult men having poor semen quality is treated with injections of human Growth Hormone (hGH) in daily doses of 1-10 IU/m.sup.2 or in doses in combination with gonadotrophins. Increase in total semen volume and total sperm number per ejaculate up to normal figures is obtained.
Abstract: Piperazinyl derivatives of the general formula I ##STR1## wherein R.sup.1 represents substituted phenyl, 1- or 2-diazanaphthyl, azadiazanaphtyl or diazanaphtyl groups; n is 1, 2, 3 or 4; X is --O-- or ##STR2## wherein R.sup.2 is hydrogen, C.sub.1-6 -alkyl or C.sub.3-8 -cycloalkyl; Y is .dbd.O or .dbd.S or .dbd.NZ wherein Z is hydrogen, C.sub.1-6 -alkyl or --CN and R.sup.3 is selected from a group consisting of various structures have been found to exhibit high affinity for various receptor subtypes including the 5-HT.sub.2 receptor, the 5-HT.sub.1A receptor, the alpha.sub.1 receptor the dopamine receptor or a combination of these and may therefore be useful for treating CNS system, cardiovascular system and gastrointestinal disorders.
Type:
Grant
Filed:
August 13, 1991
Date of Patent:
September 21, 1993
Assignee:
Novo Nordisk A/S
Inventors:
Lone Jeppesen, Marit Kristiansen, John B. Hansen
Abstract: A method for isolating Factor VIII from other proteins dissolved in blood plasma is disclosed, wherein plasma is subjected to gel filtration under group separation conditions giving a fraction containing Factor VIII in very high yield and almost free of other proteins.
Abstract: Indole derivatives of formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 may be hydrogen or lower alkyl optionally substituted by halogen; X represents oxygen or sulfur; A.sup.1 represents a straight or branched alkylene chain containing from 2 to 4 carbon atoms; R.sup.5 is hydrogen or a straight or branched alkyl group; A.sup.2 is a straight or branched, saturated or unsaturated hydrocarbon chain containing from 2 to 6 carbon atoms; and R.sup.6 is selected from a group consisting of various structures, have been found to exhibit central nervous system activities.
Type:
Grant
Filed:
September 28, 1990
Date of Patent:
July 13, 1993
Assignee:
Novo Nordisk A/S
Inventors:
Lone Jeppesen, Peter H. Andersen, Louis B. Hansen, Peter Faarup, John B. Hansen
Abstract: The present invention relates generally to the immobilization or incorporation of polypeptides, especially enzymes or other bioactive polypeptides into polymeric matrixes, especially polyurethane, membranes produced by said polymers, and the utilization of such membranes in biosensors. A preferred type of biosensor is the needle sensor designed for in vivo monitoring of glucose which comprises a core platinum anode (2) coated with an insulating lacquer (3), the anode (2) is situated inside a stainless steel reference cathode (4) which is insulated from the anode (2) by a layer of epoxy resin (5) At one end, of the tip, the electrode (1) has a detection surface (6) which is in an acute angle to the general direction of the electrode (1). At the other end, the base, the electrode (2) is provided with terminals (7) and (8) for the anode (2) and cathode (4), respectively.
Abstract: This invention is in the field of glucose isomerization enzymes. More specifically, the invention is directed to a novel xylose isomerase, a process for the preparation of this enzyme, the use of this enzyme in glucose isomerization processes, and glucose isomerization processes. The enzyme is preferably derived from Thermotoga maritima or Thermotoga neapolitana. The enzyme has a temperature optimum above 90.degree. C., pH optimum in the range of from 6 to 7 and a residual activity at 90.degree. C. of more than 40% after 30 minutes and/or residual activity at 98.degree. C. of more than 20% after 30 minutes. The enzyme can also be in immobilized form.
Type:
Grant
Filed:
October 19, 1990
Date of Patent:
June 15, 1993
Assignees:
Novo Nordisk A/S Novo Alle,, John Hopkins University
Inventors:
Robert L. Starnes, Robert M. Kelly, Stephen H. Brown
Abstract: The EPI protein is isolated and purified from a fermentation solution, using chromatographic technique, wherein the solution containing the EPI protein is applied to a matrix coupled with heparin, preferably heparin-Sepharose.
Abstract: Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl- or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy or cyano; R.sup.3 and R.sup.4 each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R.sup.5 and R.sup.6 each represents hydrogen or may--when m is 2--together represent a bond, and R.sup.7 is OH or C.sub.1-8 -alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R.sup.8 is H and C.sub.1-4 -alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.
Type:
Grant
Filed:
August 20, 1991
Date of Patent:
May 25, 1993
Assignee:
Novo Nordisk A/S
Inventors:
Lars Jacob S. Knudsen, Anker S. Jorgensen, Knud E. Andersen, Ursula Sonnewald
Abstract: Novel chemically modified detergent enzymes are provided, wherein one or more methionines have been mutated into cysteines, said cysteines subsequently being chemically modified in order to confer the enzyme improved stability towards oxidative agents. A novel process for stabilizing detergent enzymes against oxidation is also provided. Furthermore, there are provided detergent compositions comprising these novel oxidation stable detergent enzymes.
Type:
Grant
Filed:
July 17, 1990
Date of Patent:
May 4, 1993
Assignee:
Novo Nordisk A/S
Inventors:
Lene M. Bech, Sven Branner, Klaus Breddam, Hanne Groen
Abstract: Fatty acid esters of methyl glycosides are prepared by reacting a fatty acid or ester with a methyl glycoside in the presence of an enzyme catalyst, in particular a lipase. The resulting fatty acid esters are preferably monoesters.The methyl glycoside fatty acid esters may be used as surface-active agents in cleaning compositions or personal care products.
Type:
Grant
Filed:
March 16, 1990
Date of Patent:
April 6, 1993
Assignee:
Novo Nordisk A/S
Inventors:
Ole Kirk, Sven Erik Godtfredsen, Fredrik Bjorkling